Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...
Vertex Pharmaceuticals宣布ALYFTREK获得FDA批准
这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock
The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...
Cramer’s Mad Dash: Vertex Pharmaceuticals
CNBC’s Jim Cramer delivers his daily Mad Dash. Drones Banned in New Jersey Over 'Imminent Security Threat' Finnair New A350 - ...
腾讯网1 天
Vertex(VERX.US)非成瘾性止痛药遭遇“安慰剂效应” 分析师称其带来挫折
Vertex的药物suzetrigine被誉为一项科学突破，因为它阻断了一种有助于控制人体神经元活动的钠通道，在不进入大脑的情况下治疗疼痛。这使得它比阿片类药物更不容易上瘾，在截至2024年6月的一年中，阿片类药物导致约7万人因过量服用而死亡。如果获 ...
Vertex股价目标下调，但基于试验结果维持买入评级
周五，H.C. Wainwright调整了Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的股票目标价，将其从600.00美元下调至535.00美元，同时保持对该股的买入评级。根据 InvestingPro 数据，该股在过去一周下跌了近14.5%，分析师目标价范围在325美元至602美元之间。
Vertex Pharmaceuticals Faces Uncertainty with Mixed Phase 2 Trial Results
Needham analyst Joseph Stringer has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday.Pick the best stocks and ...
nai5001 天
这只消费科技股和生物科技股有一个共同点，值得持有十年以上
苹果公司（AAPL）和Vertex Pharmaceuticals（VRTX）看似没有太多共同之处。前者是一家消费科技领导者，而后者则在生物技术行业运作。然而，它们有一个共同点，那就是能让长期股东感到满意。过去十多年，苹果和Vertex ...
Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis Treatment
Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, ...
Benzinga.com1 天
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
Post-hoc analysis revealed variability in placebo response, highlighting trial design challenges for future studies. On ...
Here’s Why Vertex Pharmaceuticals Incorporated (VRTX) Slid in Q3
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...